Biovitalis, UAB - financials and debts

Company age: 15 y. 5 mo.

Update

Biovitalis - Company finances

EUR
2018
From: 2018-01-01
To: 2018-12-31
2019
From: 2019-01-01
To: 2019-12-31
2021
From: 2021-01-01
To: 2021-12-31
2022
From: 2022-01-01
To: 2022-12-31
2023
From: 2023-01-01
To: 2023-12-31
2024
From: 2024-01-01
To: 2024-12-31
2025
From: 2025-01-01
To: 2025-12-31
Financial data
Sales revenue 82,417 56,550 98,791 82,820 63,422 29,387 40,959
Profit before tax 11,842 5,585 8,257 12,294 6,291 -8,183 -3,709
Net profit 11,250 5,306 7,844 11,679 5,976 -8,183 -3,709
Equity 43,845 49,151 60,135 71,814 77,790 69,607 59,922
Liabilities 7,999 1,066 14,956 6,755 2,454 1,225 1,225
Non-current assets 4,042 3,330 1,906 1,713 1,001 11,300 10,170
Current assets 47,802 46,887 73,185 76,856 79,243 59,532 50,977
Total assets 51,844 50,217 75,091 78,569 80,244 70,832 61,147
Taxes paid
STI taxes - - - - 6,653 2,209 2,191
Financial indicators
Revenue change y/y +5.3% -31.4% - -16.2% -23.4% -53.7% +39.4%
ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. 21.7% 10.6% 10.4% 14.9% 7.4% -11.6% -6.1%
ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. 25.7% 10.8% 13.0% 16.3% 7.7% -11.8% -6.2%
Profit margin Net profit margin. Shows the overall profitability of the company. 13.7% 9.4% 7.9% 14.1% 9.4% -27.8% -9.1%
EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. 14.4% 9.9% 8.4% 14.8% 9.9% -27.8% -9.1%
Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. 0.2 0.0 0.2 0.1 0.0 0.0 0.0
Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. 82,417 56,550 98,791 82,820 63,422 29,387 40,959

Purchase full financial statements

Profit/Loss, Balance Sheet, Cash Flow, Equity

9.99 € + PVM Buy

See Scoris data in Google Search

Mark Scoris as a favorite source. One click, no registration.

Biovitalis - Social security debts

The amount of overdue SODRA debt for the company Biovitalis as of the last working day is: 4 €

From To Debt, €
2026-09-05 2026-09-14 4.25
2026-08-26 2026-09-02 4.25
2026-08-23 2026-08-23 4.25
2026-08-19 2026-08-19 4.25
2026-07-27 2026-07-28 12.98
2026-07-26 2026-07-26 12.85
2026-07-23 2026-07-25 12.98
2026-07-19 2026-07-22 12.85
2026-07-16 2026-07-17 12.85
2026-06-23 2026-07-15 8.60
2026-06-11 2026-06-22 4.35
2026-05-17 2026-06-08 4.35
2026-05-03 2026-05-14 0.10
2026-04-24 2026-04-29 0.10
2026-04-23 2026-04-23 4.35
2026-04-21 2026-04-22 4.25
2026-04-20 2026-04-20 13.16
2026-03-29 2026-04-15 8.91
2026-03-17 2026-03-27 8.91
2026-03-15 2026-03-16 4.66
2026-02-18 2026-03-11 4.66
2026-01-01 2026-01-15 14.73
2025-12-16 2025-12-30 14.73
2025-11-18 2025-12-15 9.88
2025-10-27 2025-11-17 5.03
2025-10-26 2025-10-26 4.85
2025-10-23 2025-10-25 5.03
2025-10-16 2025-10-22 4.85
2025-09-16 2025-09-23 4.85
2025-08-28 2025-08-29 19.63
2025-08-19 2025-08-25 19.63
2025-07-28 2025-08-18 14.78
2025-07-26 2025-07-27 14.56
2025-07-24 2025-07-25 14.78
2025-07-16 2025-07-23 14.56
2025-06-17 2025-07-15 9.71
2025-05-16 2025-05-26 19.61
2025-05-04 2025-05-15 9.90
2025-04-30 2025-04-30 9.71
2025-04-28 2025-04-29 9.90
2025-04-26 2025-04-27 9.71
2025-04-24 2025-04-25 9.90
2025-04-16 2025-04-23 9.71
2025-03-18 2025-03-31 19.42
2025-02-18 2025-03-17 9.71
2025-02-10 2025-02-10 13.90
2025-01-22 2025-01-27 13.90
2025-01-16 2025-01-21 13.72
2025-01-02 2025-01-15 6.86
2024-12-22 2024-12-31 6.86
2024-12-17 2024-12-20 6.86
2024-11-18 2024-11-28 14.65
2024-10-22 2024-11-17 7.79
2024-10-16 2024-10-21 6.86
2024-09-17 2024-09-25 13.72
2024-08-19 2024-09-16 6.86
2024-07-26 2024-07-28 204.25
2024-07-24 2024-07-25 396.50
2024-07-22 2024-07-23 394.78
2024-07-16 2024-07-21 13.72
2024-06-18 2024-07-15 6.86
2024-05-16 2024-05-28 13.82
2024-04-23 2024-05-15 6.96
2024-04-16 2024-04-22 6.86
2024-03-18 2024-03-26 13.86
2024-02-19 2024-03-17 7.00
2024-01-23 2024-02-18 0.14
2023-12-18 2023-12-26 7.82
2023-11-16 2023-11-23 15.94
2023-10-25 2023-11-15 8.12
2023-10-17 2023-10-24 7.82
2023-09-18 2023-09-27 23.49
2023-08-17 2023-09-17 15.67
2023-07-24 2023-08-16 7.85
2023-07-18 2023-07-23 7.82
2023-05-16 2023-05-31 6.25
2022-11-21 2022-11-28 9.46
2022-11-17 2022-11-18 9.46
2022-10-28 2022-11-16 1.73
2022-10-20 2022-10-27 7.73
2022-10-18 2022-10-19 156.15
2022-09-16 2022-09-26 156.15
2022-08-23 2022-08-28 156.15
2022-07-18 2022-07-26 157.08
2022-07-15 2022-07-17 0.93
2022-06-17 2022-06-26 155.62
2022-06-16 2022-06-16 178.81
2022-05-17 2022-06-15 22.66
2022-04-25 2022-05-16 14.93
2022-04-19 2022-04-24 14.82
2022-03-16 2022-04-18 7.09
2022-02-17 2022-02-24 7.09
2022-01-18 2022-01-25 6.92
2021-12-16 2021-12-22 6.92
2021-11-16 2021-11-22 6.92
2021-10-18 2021-10-27 6.86
2021-09-16 2021-09-26 6.86

Biovitalis - VMI tax arrears

As of 2026-09-02, the amount of overdue STI tax debt of the company Biovitalis is: 237 €

From To Overdue, €
2026-09-01 2026-09-02 237.36
2026-08-28 2026-08-31 228.0
2026-08-05 2026-08-19 2287.84
2026-08-02 2026-08-04 2286.04
2025-05-28 2025-06-26 4.75
2025-05-01 2025-05-27 8.75
2025-04-28 2025-04-30 8.63
2025-02-02 2025-02-26 8.63
2025-02-01 2025-02-01 0.84
2025-01-31 2025-01-31 1988.51
2025-01-30 2025-01-30 1987.67
2025-01-28 2025-01-29 792.67

VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.

Analysis of the company's financial position

This description was generated by artificial intelligence. Report if inaccurate.
Biovitalis, UAB (code 302617334) is a Private Limited Liability Company active in the wholesale of other household goods. In financial year 2025, the company generated revenue of €41.0K, which was 39.4% higher than in 2024, but still below the €63.4K achieved in 2023. Over the two-year period, revenue declined by 35.4% compared with 2023. Net result remained negative at €3.7K in 2025, improving from a loss of €8.2K in 2024 after a profit of €6.0K in 2023. The profit margin was -9.1% in 2025, compared with -27.8% in 2024 and 9.4% in 2023. Total assets stood at €61.1K, equity at €59.9K and liabilities at €1.2K, indicating a very strong equity position with an equity ratio of 98.0% and debt-to-equity of 0.02. Asset turnover was 0.67x. Revenue per employee was €41.0K, while profit per employee was -€3.7K. ROE and ROA were both negative in 2025, at -6.2% and -6.1% respectively.